Abstract
Aggressive behaviors have become a major public health problem, and early-onset aggression can lead to outcomes such as substance abuse, antisocial personality disorder among other issues. In recent years, there has been an increase in research in the molecular and genetic underpinnings of aggressive behavior, and one of the candidate genes codes for the catechol-O-methyltransferase (COMT). COMT is involved in catabolizing catecholamines such as dopamine. These neurotransmitters appear to be involved in regulating mood which can contribute to aggression. The most common gene variant studied in the COMT gene is the Valine (Val) to Methionine (Met) substitution at codon 158. We will be reviewing the current literature on this gene variant in aggressive behavior.
Keywords: Aggression, attention-deficit hyperactivity disorder (ADHD), catechol-0-methyltransferase (COMT), genetics, schizophrenia, Val158Met (rs4680).
Current Neuropharmacology
Title:The Role of the Catechol-o-Methyltransferase (COMT) GeneVal158Met in Aggressive Behavior, a Review of Genetic Studies
Volume: 13 Issue: 6
Author(s): Arqam Qayyum, Clement C. Zai, Yuko Hirata, Arun K. Tiwari, Sheraz Cheema, Behdin Nowrouzi, Joseph H. Beitchman and L. Kennedy
Affiliation:
Keywords: Aggression, attention-deficit hyperactivity disorder (ADHD), catechol-0-methyltransferase (COMT), genetics, schizophrenia, Val158Met (rs4680).
Abstract: Aggressive behaviors have become a major public health problem, and early-onset aggression can lead to outcomes such as substance abuse, antisocial personality disorder among other issues. In recent years, there has been an increase in research in the molecular and genetic underpinnings of aggressive behavior, and one of the candidate genes codes for the catechol-O-methyltransferase (COMT). COMT is involved in catabolizing catecholamines such as dopamine. These neurotransmitters appear to be involved in regulating mood which can contribute to aggression. The most common gene variant studied in the COMT gene is the Valine (Val) to Methionine (Met) substitution at codon 158. We will be reviewing the current literature on this gene variant in aggressive behavior.
Export Options
About this article
Cite this article as:
Qayyum Arqam, C. Zai Clement, Hirata Yuko, K. Tiwari Arun, Cheema Sheraz, Nowrouzi Behdin, Beitchman H. Joseph and Kennedy L., The Role of the Catechol-o-Methyltransferase (COMT) GeneVal158Met in Aggressive Behavior, a Review of Genetic Studies, Current Neuropharmacology 2015; 13 (6) . https://dx.doi.org/10.2174/1570159X13666150612225836
DOI https://dx.doi.org/10.2174/1570159X13666150612225836 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The HIV Pandemic: A Forgotten Crisis?
Current Drug Targets - Infectious Disorders Phenolic Acids Exert Anticholinesterase and Cognition-Improving Effects
Current Alzheimer Research Mechanisms of HIV-1 Tat Neurotoxicity via CDK5 Translocation and Hyper-Activation: Role in HIV-Associated Neurocognitive Disorders
Current HIV Research The Evolution of Pharmacological Treatment for Parkinsons Disease
Recent Patents on CNS Drug Discovery (Discontinued) A Qualitative Analysis Based on Relative Expression Orderings Identifies Transcriptional Subgroups for Alzheimer’s Disease
Current Alzheimer Research Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?
Current Pharmaceutical Design Leukocyte-mediated Tissue Injury in Ischemic Stroke
Current Medicinal Chemistry Metal Protein Attenuating Compounds (MPACs): An Emerging Approach for the Treatment of Neurodegenerative Disorders
Current Bioactive Compounds Quantitative Ultrasound in Diagnosis of Metabolic Bone Diseases
Current Medical Imaging Towards Practical Cognitive Assessment for Detection of Early Dementia: A 30-Minute Computerized Battery Discriminates as Well as Longer Testing
Current Alzheimer Research Psoriasis and Atherosclerosis: Is There a Need For Novel Biomarkers Assessing Cardiovascular Risk?
Current Pharmaceutical Design Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry Perispinal Etanercept for Treatment of Alzheimers Disease
Current Alzheimer Research Peripheral Mononuclear Cell Rejuvenation for Senescence Surveillance in Alzheimer Disease
Current Pharmaceutical Design Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry The Prevalence of Frailty in Patients Admitted to Hospital with Vertebral Fragility Fractures
Current Rheumatology Reviews Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine β-Amyloid Fibrillation and/or Hyperhomocysteinemia Modify Striatal Patterns of Hyaluronic Acid and Dermatan Sulfate: Possible Role in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Coping with Stress During Aging: The Importance of a Resilient Brain
Current Neuropharmacology